reason report
strong bar come growth rebound
pt
beat revenu govern tender
earn reliev investor concern continu
busi result compani core busi initi
guidanc consensu base
headwind clinic trial recruit experi prior
year suggest manag like increas initi
guidanc throughout year compani descript
soliri growth outlook high singl digit alarm
investor compani true underli product demand
continu complic put take one-tim
order clinic trial recruit price fx
chang near-term result baromet perform
launch myasthenia gravi mg appear
pick steam expect investor start focu valu
implic upsid approach phase
result well revenu rebound materi
patient larg clinic trial start roll
commerci product
manag disclosur quarter primari endpoint
trial lactat dehydrogenas ldh normal test
continu basi reinforc posit outlook
trial confid prospect numer statist
superior soliri alexion manag reiter
small number advers event seen clinic experi
compani commit increas resourc develop
commerci invest base quarter result
manag commentari guidanc updat
model estim larg unchang ex-u
strensiq forecast reduc base slower develop market
earn estim adjust slower improv
oper margin compani new higher tax rate guidanc
base lower estim significantli lower multipl
compar peer compani reduc price target
maintain outperform rate stock continu
convict outlook trial durabl
revenu cash flow franchis opportun
recent launch mg indic contribut substanti revenu
adjust price target offer upsid current market
disloc believ offer one predict
attract opportun group
net debt total capit
price-to-earnings lt ep growth
averag dcf price-to-earnings
compani inform leerink partner llc research
revenu mm ep exclud option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
price target rate stock
outperform alexion lead independ compani develop commerci
treatment ultra-rar disord complement system nearli revenu today
come soliri approv two differ rare diseas indic believ
alexion increas current revenu run rate complement franchis
competit threat soliri overst view given long safeti
efficaci histori soliri well alexion progress develop improv version
product greater potenc longer half-lif conveni dose beyond soliri alexion
recent began global launch two addit rare diseas medicin kanuma
strensiq expect contribut approxim combin revenu
alexion maintain reason financi disciplin expect oper margin
bounc back better drop acquisit
synageva cost two product launch alexion remain
one fastest grow busi biopharmaceut durabl larg molecul
protein therapi believ soon recov multipl premium peer
three product contribut revenu total revenu beat consensu
estim grew qoq yoy although alexion indic
quarter benefit govern tender quarter soliri drove
upsid sale beat consensu us call
manag indic new mg indic provid minim contribut quarter
result strensiq sale beat consensu kanuma sale beat
consensu howev kanuma benefit govern tender book
previou defer revenu estim unlik increas significantli
ep revenu lower tax alexion oper expens
consensu expect reflect advanc compani restructur effort
began oper expens reduct mainli lower expenditur
discontinu pipelin product sg higher
consensu come significantli second half headcount
reduct fulli implement tax rate consensu help
boost non-gaap ep beat beat compar consensu miss
compar estim reflect acceler restructur save
conserv guidanc consensu expect rais manag
provid initi guidanc similar segment last year initi figur
conserv expect estim alexion histor rais revenu ep
guidanc year would expect similar magnitud product sale
guid consensu midpoint
estim revenu guidanc includ unfavor soliri
headwind lost patient clinic trial off-set partial fx benefit
soliri revenu guidanc metabol revenu
guidanc rang recent consensu estim
although investor anticip cautiou initi year guidanc non-
 guid non- sg guid lead
guid oper margin recent consensu expect oper margin
consensu oper expens decreas margin due guidanc
anticip alexon neg impact new us tax law due loss orphan drug
credit guid tax rate compar consensu
result non-gaap ep guidanc consensu materi
estim manag indic would difficult growth compar
revenu oper margin would benefit easier compar less expens
growth signific increment mg revenu importantli manag
acknowledg substanti bolu clinic trial patient accumul open
label continu phase ii phase trial patient
like transit commerci rel quickli drug approv reimburs
respect territori trial conduct ultim
bolster share increas treatment penetr given increas conveni long term
avail subcutan self-inject version bring even patient
treatment well minim market share loss new competitor
mg launch current captur patients/month alexion disclos approxim
commerci live polici coverag soliri mg process medic
educ neurologist neuromuscular specialist on-going alexion report
patient enrol alexion patient assist program patient
start drug importantli mani prescrib physician clinic
investig earli adopt new therapeut option mani regain
extens studi patient switch commerci therapi base
previou patient initi updat januari rate alexion ad mg patient month
therapi rate patient accrual continu increas
new phase disclosur increas confid trial success written
extens phase trial believ high likelihood
demonstr non-inferior superior treatment-nav patient see
note phase iii know bar surpris
super-ior number wide margin efficaci previous
disclos clinic protocol time point primari endpoint ldh normal
would measur call alexion clarifi endpoint would calcul
odd ratio base continu measur day week trial
believ protocol benefit phase ii data show patient
fluctuat normal ldh level upper limit normal uln would
benefit odd ratio never seen evid soliri normal ldh
level time point word measur frequenc increas chanc
normal patient like impact probabl
normal soliris-tr patient breakthrough hemolysi endpoint trial
defin increas ldh uln fall uln least one
physician-identifi associ symptom breakthrough hemolysi previous
disclos manag offer expect soliri arm endpoint alexion believ
criteria stricter anecdot report breakthrough hemolysi real world
definit use prior trial compani expect rate soliri use
definit less commonli report alexion disclos
endpoint calcul treatment differ odd ratio etc non-inferior margin
would still expect favor differ given drug superior impact
ldh reduct critic role ldh defin breakthrough hemolysi
paroxysm nocturn hemoglobinuria pnh soliri neuromyel optica
nmo phase confirm disclosur alexion provid increment key pipelin
regulatori updat quarterli report howev manag re-affirmed time
two import catalyst year pnh non-inferior studi still
anticip data soliri nmo studi still expect data mid-
later year phase ahu studi data report
alexion initi bridg studi weekli subcutan version pnh
leerink strensiq forecast reduc ep adjust higher tax rate lower ep
updat model base quarter result manag comment
guidanc biggest chang estim strensiq forecast ex-u
materi degre percentag us revenu achiev soliri
lower ex-u strensiq forecast turn lower global
strensiq forecast total revenu unchang lower
forecast lower recent consensu period though
consensu like come year guidanc given trajectori expens
time progress restructur effort increas sg estim
lower oper margin signific
chang model tax rais tax rate period result
chang pro forma ep estim decreas
adjust pro forma ep consensu
lower expect consensu ep estim come base
higher sg expens tax rate guidanc base neg revis
model reduc price target maintain outperform
rate alexion stock
price target base simpl averag three
approach believ reason basi valu stock today approach
simpl price earn multipl compar large-cap biopharma compani
celg growth adjust near-term earn multipl ratio
discount cash flow dcf use rel multipl similar growth compani
ep appli ep estim alexion give fair valu
stock use expect ep compound-annual-growth-rate alexion period
current averag ratio larg molecul large-cap biotech give ep
multipl discount multipl compress alexion
appli ep estim give fair valu final dcf use
termin growth rate post give current valu averag three
approach price target alexion stock
risk view outlook valuat alexion includ major chang price
reimburs coverag label soliri compani main product today risk
includ commerci develop disappoint recent launch product strensiq
kanuma well develop disappoint addit indic soliri
successor complement inhibitor product final brand gener competitor
product soliri come market captur greater share caus greater market price
disrupt current expect futur outlook valuat would undermin
opportun better perform valu expect includ stronger initi
adopt recent launch new product forecast success develop
commerci new indic soliri beyond neuromyel optica myasthenia
gravi novel rare diseas medicin time horizon forecast
sale non-gaap
share count period dilut
guidanc
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
time
result pivot pnh
result pivot ahu
leerink partner research compani report present clinicaltri gov
late stage pipelin program includ
late stage pipelin program exclud
million
leerink partner research compani file
million
good sold
 total revenu
sg total revenu
leerink partner research compani file
analysi stock price leerink target alexion
method today larg cap brand biopharma futur ep multipl ep
leerink estimate earn
current averag larg cap biopharma multipl ep
leerink adjust ep estim
capit
number period
impli target price
method leerink intrins valu base dcf current product net
current leerink dcf marketed/l stage program
current estim valu asset
method project forward earn multipl ep base ep
compound-annual-growth-rate larg cap biotech ratio
averag larg molecul larg cap biopharma co
impli ep multipl discount vs full multipl
averag method
leerink partner research compani file factset
